JPS6232727B2 - - Google Patents
Info
- Publication number
- JPS6232727B2 JPS6232727B2 JP1087883A JP1087883A JPS6232727B2 JP S6232727 B2 JPS6232727 B2 JP S6232727B2 JP 1087883 A JP1087883 A JP 1087883A JP 1087883 A JP1087883 A JP 1087883A JP S6232727 B2 JPS6232727 B2 JP S6232727B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- serum cholesterol
- administration
- groups
- experimental example
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000003529 anticholesteremic agent Substances 0.000 claims description 4
- 229940127226 anticholesterol agent Drugs 0.000 claims description 4
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229960001214 clofibrate Drugs 0.000 description 5
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000282564 Macaca fuscata Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- -1 and mannitrate Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- POFDSYGXHVPQNX-UHFFFAOYSA-N triazolo[1,5-a]pyrimidine Chemical compound C1=CC=NC2=CN=NN21 POFDSYGXHVPQNX-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1087883A JPS58192823A (ja) | 1983-01-26 | 1983-01-26 | 血清コレステロ−ル低下剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1087883A JPS58192823A (ja) | 1983-01-26 | 1983-01-26 | 血清コレステロ−ル低下剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6790178A Division JPS54160745A (en) | 1978-06-06 | 1978-06-06 | Circulatory disease treating agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58192823A JPS58192823A (ja) | 1983-11-10 |
| JPS6232727B2 true JPS6232727B2 (de) | 1987-07-16 |
Family
ID=11762581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1087883A Granted JPS58192823A (ja) | 1983-01-26 | 1983-01-26 | 血清コレステロ−ル低下剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58192823A (de) |
-
1983
- 1983-01-26 JP JP1087883A patent/JPS58192823A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58192823A (ja) | 1983-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6051587A (en) | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein | |
| EP0546796A1 (de) | Verwendung von L-Arginin und seinen Analogen zur Behandlung von Atherosklerosis | |
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| JP3018160B2 (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤 | |
| US4766117A (en) | Antiinflammatory compositions and methods | |
| US4579846A (en) | Antiinflammatory compositions and methods | |
| EP0629400A1 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| US5416105A (en) | Treating an arteriosclerosis with glimepiride | |
| JPH0140009B2 (de) | ||
| JPH0121132B2 (de) | ||
| KR20070086007A (ko) | 당뇨병의 치료를 위한 의약 조성물 | |
| JPS647045B2 (de) | ||
| JPS6232727B2 (de) | ||
| CA2335280C (en) | Method of treating pulmonary hypertension | |
| US4874757A (en) | Antinflammatory compositions and methods | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| US4593031A (en) | Method of treating depression | |
| JPS6081127A (ja) | 食欲抑制剤 | |
| JPS63198630A (ja) | 脂質代謝改善剤 | |
| DE60016038T2 (de) | Neue verwendung von levosimendan | |
| US4812455A (en) | Antiinflammatory compositions and methods | |
| JPH09227371A (ja) | 粥状動脈硬化抑制剤 | |
| HU212941B (en) | Process for producing synergetic, antihypertensive pharmaceutical compositions containing verapamil and trandolapril | |
| JPH0220608B2 (de) | ||
| GB2098864A (en) | Pharmaceutical preparation containing a guanidiine compound and a diuretic |